FDA Approves Zanubrutinib (Brukinsa) for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

MONDAY, Jan. 23, 2023 -- The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The approval was...